



## **ABOLOGIX founded in Geneva, Switzerland**

- **The company, based in Geneva, will develop monoclonal antibodies for the treatment of difficult to manage hematological and solid tumours**
- **The initial focus will be on the blocking of two novel pharmacological targets: JAM-C (Junction Adhesion Molecule C) and Olfml3 (matricellular protein Olfactomedin-like 3)**
- **Abologix capitalizes on the work done for over 10+ years on these two targets at the laboratories of Prof. Beat Imhof and Thomas Matthes at the University of Geneva and the Hôpitaux Universitaires de Genève**

### **Geneva, Switzerland, January 25, 2018.**

Abologix was launched today, and it is the newest addition to the biotechnology ecosystem in the city of Geneva (Switzerland).

The three founders of Abologix are Dr. Ignacio Faus, Prof. Beat Imhof and Prof. Thomas Matthes.

The company intends to develop novel monoclonal antibodies for the treatment of JAM-C positive hematological tumours.

New therapeutics for the treatment of difficult to manage solid tumours will be developed by blocking the Olfml3 target.

Dr. Ignacio Faus has been named Chairman of the Board of the company. He has more than 20+ years of experience in the pharmaceutical and biotechnology industries, in companies both in the USA and in Europe.

## **About Abologix**

Abologix is a pre-clinical stage biopharmaceutical company developing best-in-class monoclonal antibodies by blocking the Junction Adhesion Molecule **JAM-C** and the extracellular matrix-related protein **Olfactomedin-like protein 3 (Olfml3)** for the treatment of hematological and solid cancers. The company is based in Geneva (Switzerland) and it is a spin-out from the laboratories of Profs. Beat Imhof and Thomas Matthes at the University of Geneva and the Hôpitaux Universitaires de Genève.

## **Contact Information**

Ignacio Faus, Chairman of the Board

Abologix Sàrl

[ignaciofaus@abologix.com](mailto:ignaciofaus@abologix.com)